Nathan H. Fowler

Hematology
1515 Holcombe Blvd Unit 429
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 196 publications

Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.

Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.

Journal: Research square
Published: August 20, 2026

Structure of a key adhesin-exopolysaccharide interaction provides insights into matrix assembly in Vibrio cholerae biofilms.

Structure of a key adhesin-exopolysaccharide interaction provides insights into matrix assembly in Vibrio cholerae biofilms.

Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026

Conformational dynamics of exopolysaccharides underlie biofilm matrix mechanics in Vibrio cholerae.

Conformational dynamics of exopolysaccharides underlie biofilm matrix mechanics in Vibrio cholerae.

Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026

Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 13, 2026

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 16, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood
Published: January 13, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood
Published: January 13, 2026

Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma.

Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma.

Journal: Blood advances
Published: December 22, 2025

Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.

Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.

Journal: Cancer discovery
Published: July 25, 2025

MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomics.

MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomics.

Journal: Human genetics
Published: May 22, 2025

A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.

A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.

Journal: Blood advances
Published: March 12, 2025

Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.

Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.

Journal: Haematologica
Published: January 11, 2025
Showing 1-12 of 196

Last Updated: 09/26/2026